Microsoft To Rally More Than 40%? Here Are 10 Top Analyst Forecasts For Thursday
Microsoft To Rally More Than 40%? Here Are 10 Top Analyst Forecasts For Thursday
View filing at SEC.gov →7 most recent filings and news items mentioning IONS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/IONS/news?limit=20"
Pull IONS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMicrosoft To Rally More Than 40%? Here Are 10 Top Analyst Forecasts For Thursday
View filing at SEC.gov →Ionis exceeded revenue expectations with a 56% increase compared to the prior year, driven by commercial success and partnerships. The company remains on track to achieve 2026 guidance and reported a strong cash balance of $2.1 billion.
View filing at SEC.gov →10 Health Care Stocks With Whale Alerts In Today’s Session
View filing at SEC.gov →The CARDIO-TTRansform trial for eplontersen did not meet its primary cardiovascular endpoint vs. placebo, though a positive signal was seen in monotherapy. The missed readout presents a setback for the drug's add-on therapy strategy, potentially weighing on the stock despite posi
View filing at SEC.gov →Ionis Pharmaceuticals announced the FDA approval of olezarsen (Tryngolza), a new treatment for severe hypertriglyceridemia. This marks the company's first independent commercial launch in a prevalent disease and is designed to significantly reduce acute pancreatitis risk in patie
View filing at SEC.gov →Ionis Pharmaceuticals announced the appointment of Ludwig Hantson, Ph.D., a veteran biopharma executive with 30+ years of experience including CEO roles at Alexion and Baxalta, to its Board of Directors effective immediately. The appointment strengthens board expertise as Ionis p
View filing at SEC.gov →GSK announced positive Phase 3 pivotal data for bepirovirsen, Ionis's antisense oligonucleotide, showing a 19% functional cure rate versus 0% with standard of care in chronic hepatitis B patients. The results represent significant commercial potential for Ionis through its partne
View filing at SEC.gov →